Investor's Business Daily on MSN27m
Biogen Hammered As Lackluster Guidance Drags On Fourth-Quarter BeatBiogen stock took a hit Wednesday after the biotech company issued light guidance for 2025 despite beating most fourth-quarter expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback